The above results strongly suggest that ALOX5 may be capable of modulating the ccRCC-associated immune microenvironment by influencing immune cell populations capable of promoting tumor growth including plasma cells, activated memory T cells, Tfh cells, Tregs, and M0 macrophages, resulting in the impairment of normal lipid metabolism and poor prognostic outcomes. This evidence concerns the gene ALOX5 and nonpapillary renal cell carcinoma.